QR Code

Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson’s disease

Background: Dysphagia is a potentially fatal symptom of Parkinson’s disease (PD) and is characterized by frequent silent aspiration, a known risk factor for aspiration pneumonia. A previous study has reported that the dopamine agonist rotigotine (levodopa equivalent dose of 60 mg/day) delivered via...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Makito Hirano, Makoto Samukawa, Chiharu Isono, Rino Inada, Yuta Fukumoto, Keisuke Yoshikawa, Hitoshi Namura, Hanami Sakata, Takahiro Hisatomi, Toru Michiura, Hiroto Nakamura, Akira Morita, Genki Hoshino, Kensuke Yamana, Atsushi Terayama, Yuji Higashimoto, Yoshiyuki Mitsui, Yoshitaka Nagai
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2025-01-01
Rangatū:Clinical Parkinsonism & Related Disorders
Ngā marau:
Dysphagia
Parkinson’s disease
DOSS
Deglutition
CSCI of foslevodopa/foscarbidopa
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S2590112525000829
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite